v3.23.2
Condensed Consolidated Balance Sheets - USD ($)
Jun. 30, 2023
Dec. 31, 2022
Current assets:    
Cash $ 2,912,920 $ 5,353,392
Advances on research and development contract services 78,015 147,017
Prepaid insurance 54,650 49,224
Other prepaid expenses and current assets 49,563 10,380
Total current assets 3,095,148 5,560,013
Total assets 3,095,148 5,560,013
Current liabilities:    
Accounts payable and accrued expenses, including $42,500 and $46,982 to related parties at June 30, 2023 and December 31, 2022, respectively 366,528 229,764
Research and development contract liabilities 36,086 165,022
Total current liabilities 402,614 394,786
Commitments and contingencies
Stockholders’ equity:    
Preferred Stock, $0.0001 par value; authorized – 10,000,000 shares; issued and outstanding – 350,000 shares of Series A Convertible Preferred Stock, $10.00 per share stated value, liquidation preference based on assumed conversion into common shares – 72,917 shares 3,500,000 3,500,000
Common stock, $0.0001 par value; authorized – 100,000,000 shares; issued and outstanding – 1,665,956 shares and 1,664,706 shares at June 30, 2023 and December 31, 2022, respectively 166 166
Additional paid-in capital 45,623,081 45,059,760
Accumulated deficit (46,430,713) (43,394,699)
Total stockholders’ equity 2,692,534 5,165,227
Total liabilities and stockholders’ equity $ 3,095,148 $ 5,560,013

Source

PDF HTML
10-Q Filing
ZIP XLS HTML
XBRL